B

BioNote Inc
KRX:377740

Watchlist Manager
BioNote Inc
KRX:377740
Watchlist
Price: 4 720 KRW 1.51% Market Closed
Market Cap: 481.3B KRW
Have any thoughts about
BioNote Inc?
Write Note

BioNote Inc
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

BioNote Inc
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
B
BioNote Inc
KRX:377740
Income from Continuing Operations
-â‚©20.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Celltrion Inc
KRX:068270
Income from Continuing Operations
â‚©320.9B
CAGR 3-Years
-19%
CAGR 5-Years
7%
CAGR 10-Years
10%
SK Bioscience Co Ltd
KRX:302440
Income from Continuing Operations
â‚©22.3B
CAGR 3-Years
-12%
CAGR 5-Years
20%
CAGR 10-Years
N/A
H
Hugel Inc
KOSDAQ:145020
Income from Continuing Operations
â‚©119.4B
CAGR 3-Years
20%
CAGR 5-Years
17%
CAGR 10-Years
N/A
P
PharmaResearch Co Ltd
KOSDAQ:214450
Income from Continuing Operations
â‚©90.8B
CAGR 3-Years
28%
CAGR 5-Years
47%
CAGR 10-Years
N/A
Alteogen Inc
KOSDAQ:196170
Income from Continuing Operations
-â‚©5.1B
CAGR 3-Years
41%
CAGR 5-Years
11%
CAGR 10-Years
N/A
No Stocks Found

BioNote Inc
Glance View

Market Cap
481.7B KRW
Industry
Biotechnology

BioNote, Inc. develops veterinary diagnostic composition. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2022-12-22. The firm is engaged in the manufacture and sale of rapid diagnostic kits for humans, diagnosis raw materials such as antigens, antibody cell lines, standards, enzymes and others as well as semi-finished products. The firm is also engaged in the manufacture and sale of rapid immunochemical diagnosis, enzyme immune rebound protein, immunochemical fluorescence diagnosis and other products used for animals.

Intrinsic Value
4 394.57 KRW
Overvaluation 7%
Intrinsic Value
Price
B

See Also

What is BioNote Inc's Income from Continuing Operations?
Income from Continuing Operations
-20.5B KRW

Based on the financial report for Dec 31, 2023, BioNote Inc's Income from Continuing Operations amounts to -20.5B KRW.

Back to Top